Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

260 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-01-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to improve the accuracy of diagnosis for children and adolescents with MDS by a standardized review of morphology and standardized cytogenetic and molecular analysis.

The primary objectives of the study are:

* To evaluate the frequency of the different subtypes of MDS in childhood and adolescence by a standardized diagnostic approach
* To evaluate the frequency of cytogenetic and molecular abnormalities:

Specifically using array-CGH to evaluate the frequency of subtle chromosomal imbalances, i.e. gains and losses of defined chromosomal regions, and amplifications.

Specifically using mFISH to identify unknown chromosomal aberrations, particularly subtle translocations involving new candidate genes, and to better define chromosomal breakpoints.

The secondary objectives of the study are:

* To assess survival for children and adolescents with MDS and JMML
* To evaluate relapse rate, morbidity and mortality in children with MDS and JMML treated by HSCT

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes

NCT00600860

Myelodysplastic Syndromes (MDS)

UNKNOWN

Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

NCT04460950

Acute Myeloid Leukemia Familial Acute Myeloid Leukemia Myelodysplastic Syndromes

RECRUITING

Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00003790

Leukemia Myelodysplastic Syndromes

COMPLETED

Sterile Inflammation and Molecular Aberrations in MDS

NCT04313231

Myelodysplastic Syndromes

UNKNOWN

Targeted High Throughput Sequencing in the Diagnosis of Pediatric Acute Leukemia

NCT01991249

Pediatric Acute Leukemia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelodysplastic Syndromes Juvenile Myelomonocytic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent by the caretakers and whenever possible the patient's assent.
* Confirmed diagnosis of MDS or JMML (morphology, cytogenetics)
* Myeloid leukemia of Down syndrome (patients aged \> 6 years).
* Age less than 18 years

Exclusion Criteria

* Denied informed consent and/or assent by caretakers/patient.
* Myeloid leukemia of Down syndrome (patients \< 6 years).
* Participation in another study within the last 4 weeks (except for therapy optimizing studies in cancer or bone marrow failure disorders and studies in diagnostics).

Maximum Eligible Age

215 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No